Researchers Develop Mass Spec Reference Method for Measuring Amyloid Beta 42 in Alzheimer's Patients | GenomeWeb

NEW YORK (GenomeWeb News) – An international consortium of researchers has developed a mass spectrometry-based reference method for standardizing measurements of cerebrospinal fluid amyloid beta 42 levels in Alzheimer's disease research and clinical work.

The method will allow researchers and clinicians to compare CSF Aβ42 measurements made with different assays in different labs, something that is currently not possible due to differences between these assays, said Henrik Zetterberg, a researcher at Sweden's Gothenburg Universityand one of the leaders of the effort.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.